Tokushima University / Educator and Researcher Directory --- Hara, Keijiro

Search:

Tokushima University ⟩ University Hospital ⟩ Central Clinical Facilities ⟩ Regioal Neurosurgery ⟩
Tokushima University ⟩ University Hospital ⟩ Clinical Division ⟩ Department of Neurosurgery, Psychiatry and Anesthesiology ⟩ Neurosurgery ⟩

(Files for researchmap) [PDF manual] [Auto-propagate to researchmap]

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Kohei Muto, Ryosuke Miyamoto, Yuka Terasawa, Yoshimitsu Shimatani, Keijiro Hara, Takumi Kakimoto, Tatsuya Fukumoto, Yusuke Osaki, Koji Fujita, Masafumi Harada, Hisanori Uehara, Yasushi Takagi and Yuishin Izumi : A novel COL4A1 variant associated with recurrent epistaxis and glioblastoma, Human Genome Variation, Vol.8, No.1, 18, 2021. (Tokushima University Institutional Repository) ● Metadata: 116530 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41439-021-00150-0 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-85105944271 (Tokushima University Institutional Repository: 116530, DOI: 10.1038/s41439-021-00150-0, Elsevier: Scopus)
2.	Toshitaka Fujihara, Yoshifumi Mizobuchi, Kohhei Nakajima, Teruyoshi Kageji, Kazuhito Matsuzaki, KT Kitazato, Ryotaro Otsuka, Keijiro Hara, Hideo Mure, Toshiyuki Okazaki, Kazuyuki Kuwayama, Shinji Nagahiro and Yasushi Takagi : Down-regulation of MDR1 by Ad-DKK3 via Akt/NFB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model, Journal of Neuro-Oncology, Vol.139, No.2, 323-332, 2018. (Summary) Glioblastoma multiforme (GBM) is the most malignant of brain tumors. Acquired drug resistance is a major obstacle for successful treatment. Earlier studies reported that expression of the multiple drug resistance gene (MDR1) is regulated by YB-1 or NFκB via the JNK/c-Jun or Akt pathway. Over-expression of the Dickkopf (DKK) family member DKK3 by an adenovirus vector carrying DKK3 (Ad-DKK3) exerted anti-tumor effects and led to the activation of the JNK/c-Jun pathway. We investigated whether Ad-DKK3 augments the anti-tumor effect of temozolomide (TMZ) via the regulation of MDR1. GBM cells (U87MG and U251MG), primary TGB105 cells, and mice xenografted with U87MG cells were treated with Ad-DKK3 or TMZ alone or in combination. Ad-DKK3 augmentation of the anti-tumor effects of TMZ was associated with reduced MDR1 expression in both in vivo and in vitro studies. The survival of Ad-DKK3-treated U87MG cells was inhibited and the expression of MDR1 was reduced. This was associated with the inhibition of Akt/NFκB but not of YB-1 via the JNK/c-Jun- or Akt pathway. Our results suggest that Ad-DKK3 regulates the expression of MDR1 via Akt/NFκB pathways and that it augments the anti-tumor effects of TMZ in GBM cells. (Tokushima University Institutional Repository) ● Metadata: 112895 (Link to Publication Site) ● Publication site (DOI): 10.1007/s11060-018-2894-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29779087 ● Summary page in Scopus @ Elsevier: 2-s2.0-85047143200 (Tokushima University Institutional Repository: 112895, DOI: 10.1007/s11060-018-2894-5, PubMed: 29779087, Elsevier: Scopus)
3.	Keijiro Hara, Teruyoshi Kageji, Yoshifumi Mizobuchi, Keiko T. Kitazato, Toshiyuki Okazaki, Toshitaka Fujihara, Kohhei Nakajima, Hideo Mure, Kazuyuki Kuwayama, Tomoyo Hara and Shinji Nagahiro : Blocking of the interaction between Wnt proteins and their co-receptors contributes to the anti-tumor effects of adenovirus-mediated DKK3 in glioblastoma, Cancer Letters, Vol.356, 496-505, 2015. (Summary) The effect of the third member of the Dickkopf family (DKK3) in the Wnt pathway in glioblastoma remains unclear. We first demonstrated the non-specific interaction of Wnt3a and Wnt5a with the receptors LRP6 and ROR2 and the up-regulation of the Wnt pathway in glioblastoma cells. We used an adenovirus vector and found that an increase in DKK3 protein attenuated the expression of Wnt3a, Wnt5a and LRP6, but not of ROR2, and their interaction, thereby affecting both canonical- and non-canonical Wnt downstream cascades. This produced anti-tumor effects in GBM xenograft models. The suppression of Wnt pathways upstream by DKK3 may have promise for the treatment of glioblastoma. (Keyword) Adenoviridae / Animals / apoptosis / Blotting, Western / cell proliferation and differentiation / Flow Cytometry / Genetic Vectors / Glioblastoma / Humans / Immunoenzyme Techniques / Immunoprecipitation / Intercellular Signaling Peptides and Proteins / Low Density Lipoprotein Receptor-Related Protein-6 / male / Mice / Mice, Inbred BALB C / Mice, Nude / Proto-Oncogene Proteins / RNA, Messenger / Real-Time Polymerase Chain Reaction / Receptor Tyrosine Kinase-like Orphan Receptors / Reverse Transcriptase Polymerase Chain Reaction / Tumor Cells, Cultured / Wnt Proteins / Wnt3A Protein / Xenograft Model Antitumor Assays (Tokushima University Institutional Repository) ● Metadata: 106342 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.canlet.2014.09.045 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25301448 ● Summary page in Scopus @ Elsevier: 2-s2.0-84919491383 (Tokushima University Institutional Repository: 106342, DOI: 10.1016/j.canlet.2014.09.045, PubMed: 25301448, Elsevier: Scopus)
4.	Toshiyuki Okazaki, Teruyoshi Kageji, Kazuyuki Kuwamura, Keiko T. Kitazato, Hideo Mure, Keijiro Hara, Ryoma Morigaki, Yoshifumi Mizobuchi, Kazuhito Matsuzaki and Shinji Nagahiro : Up-regulation of endogenous PML induced by a combination of interferon-beta and temozolomide enhances p73/YAP-mediated apoptosis in glioblastoma, Cancer Letters, Vol.323, No.2, 199-207, 2012. (Summary) Interferon-beta (IFN-) is reported to augment anti-tumor effects by temozolomide in glioblastoma via down-regulation of MGMT. Promyelocytic leukemia (PML), a gene induced by IFN-, is a tumor suppressor. Here, we report for the first time that in combination therapy, an IFN--induced increase in endogenous PML contributes to anti-tumor effects in p53 wild- and mutant glioma cells in a xenograft mice model. The increased PML promoted the accumulation of p73, a structural and functional homolog of p53, to fuse the coactivator Yes-associated-protein in the PML nuclear bodies. The adjuvant therapy targeted at PML may be a promising therapeutic strategy for glioblastoma. (Keyword) Apoptosis / Base Sequence / Blotting, Western / Brain Neoplasms / Cell Line, Tumor / DNA Primers / DNA-Binding Proteins / Dacarbazine / Glioblastoma / Humans / Interferon-beta / Nuclear Proteins / Real-Time Polymerase Chain Reaction / Transcription Factors / Tumor Suppressor Proteins / Up-Regulation (Link to Publication Site) ● Publication site (DOI): 10.1016/j.canlet.2012.04.013 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22542810 ● Search Scopus @ Elsevier (PMID): 22542810 ● Search Scopus @ Elsevier (DOI): 10.1016/j.canlet.2012.04.013 (DOI: 10.1016/j.canlet.2012.04.013, PubMed: 22542810)

Proceeding of International Conference:

1.	Toshitaka Fujihara, Teruyoshi Kageji, Yoshifumi Mizobuchi, Keijiro Hara, Kenji Shouno, Kohhei Nakajima, Hideo Mure, Kazuyuki Kuwayama and Shinji Nagahiro : Down-regulation of MDR1 by DKK3 attenuates chemoresistance to temozolomide, and potentiates its anti-tumor effects, 20th Annual Socientific Meeting and Education Day of the Society for Neuro-Oncology, Nov. 2015.
2.	Yoshifumi Mizobuchi, T Okazaki, Teruyoshi Kageji, Kazuyuki Kuwayama, KT Kitazato, Hideo Mure, Keijiro Hara, Ryoma Morigaki, Kazuhito Matsuzaki, Kohhei Nakajima, T Fujihara and Shinji Nagahiro : A combination of interferon-beta and temozolomide augments anti-tumor effects through p73/YAP-mediated apoptosis by PML in glioblastoma, The 4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in conjunction with the 2013 SNO Scientific Meeting and Education Day, San Francisco, Nov. 2013.
3.	Keijiro Hara, Teruyoshi Kageji, Yoshifumi Mizobuchi, T Okazaki, T Fujihara, Kohhei Nakajima, Hideo Mure, Kazuyuki Kuwayama, T Hara and Shinji Nagahiro : REIC/Dkk-3, one of Dickkopf(Dkk)family members, contributes to the anti-tumor effects in glioblastoma through regulation of both Wnt signal pathways, The 4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in conjunction with the 2013 SNO Scientific Meeting and Education Day, San Francisco, Nov. 2013.
4.	Kohhei Nakajima, Keijiro Hara, Teruyoshi Kageji, Yoshifumi Mizobuchi, KT KItazato, T Fujihara, Kazuyuki Kuwayama, R Otsuka, DK Kung and Shinji Nagahiro : Down-regulation of MDR by Ad-REIC contributes to augment the chemotherapy by temozolomide, The 4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in conjunction with the 2013 SNO Scientific Meeting and Education Day, San Francisco, Nov. 2013.

Proceeding of Domestic Conference:

1.	Toshitaka Fujihara, Kohhei Nakajima, Keijiro Hara, Mai Azumi, Taku Matsuda, Yoshiteru Tada and Yasushi Takagi : 脳腫瘍生検術におけるStealth Autoguideの初期使用経験, 日本脳神経外科学会第82回学術集会, Oct. 2023.
2.	Kohhei Nakajima, Mai Azumi, Toshitaka Fujihara, Keijiro Hara and Yasushi Takagi : Sellar atypical teratoid/rhabdoid tumor の1例, 第28回日本脳腫瘍の外科学会, Sep. 2023.
3.	手島奈津美, Mai Azumi, Kohhei Nakajima, Tomohiro Matsuda, Izumi Yamaguchi, Toshitaka Fujihara, Shu Sogabe, Keijiro Hara and Yasushi Takagi : 術後管理に難渋した頭蓋咽頭腫の1例, 第95回日本脳神経外科学会中国四国支部学術集会, Apr. 2023.
4.	Mai Azumi, Toshitaka Fujihara, Keijiro Hara, Kohhei Nakajima, Yoshifumi Mizobuchi and Yasushi Takagi : Examination about the predictors of outcome at discharge in postoperative brain tumor patients admitted to the intensive care units, 日本脳神経外科学会第81回学術総会, Sep. 2022.
5.	Keijiro Hara, Yoshifumi Mizobuchi, Mai Azumi, Shu Sogabe, Toshitaka Fujihara, Kohhei Nakajima and Yasushi Takagi : Hyper vascularityを呈した松果体部腫瘍の1例, 第93回日本脳神経外科学会中国四国支部学術集会, Apr. 2022.
6.	Toshitaka Fujihara, Yoshiteru Tada, Yoshifumi Mizobuchi, Kohhei Nakajima, Keijiro Hara, Mai Azumi and Yasushi Takagi : Epilepsy and perioperative seizure management in surgical cases of supratentorial meningioma, 日本脳神経外科学会第80回学術総会, Oct. 2021.
7.	Mai Azumi, Takeshi Miyamoto, Toshitaka Fujihara, Kohhei Nakajima, Keijiro Hara, Yoshifumi Mizobuchi and Yasushi Takagi : 特発性頭蓋内圧亢進様の症状のみで発症した小児脳腫瘍の1例, 第35回中国四国脳腫瘍研究会, Sep. 2021.
8.	Keijiro Hara, Yoshifumi Mizobuchi, Mai Azumi, Kohhei Nakajima and Yasushi Takagi : AIDS関連トキソプラズマ脳症の1例, 第91回(一社)日本脳神経外科学会中国四国支部学術集会, Apr. 2021.
9.	Keijiro Hara, Kyoko Nishi, Junichiro Satomi and Shinji Nagahiro : High flow bypassとdistal occlusionを行った中大脳動脈血栓化紡錘状動脈瘤の一例, 第76回(一社)日本脳神経外科学会中国四国支部学術集会, Dec. 2013.
10.	Keijiro Hara, Yoshifumi Mizobuchi, 北里慶子, 岡﨑敏之, Teruyoshi Kageji, Shinji Nagahiro and 公文裕巳 : 悪性神経膠腫におけるREIC/Dkk-3遺伝子導入によるWnt蛋白制御の意義, 第13回日本分子脳神経外科学会, Sep. 2012.
11.	岡﨑敏之, Kazuhito Matsuzaki, Yoshifumi Mizobuchi, 北里慶子, Teruyoshi Kageji, Keijiro Hara and Shinji Nagahiro : 膠芽腫に対するテモゾロミドとインターフェロンβ併用療法におけるPMLの役割, 徳島脳腫瘍セミナー2010, Feb. 2010.

Et cetera, Workshop:

1.	Mai Azumi, Kohhei Nakajima, Toshitaka Fujihara, Keijiro Hara and Yasushi Takagi : リツシマブ併用大量療法が奏功した難治性中枢神経原発悪性リンパ腫の1例, 第37回中四国脳腫瘍研究会, Sep. 2023.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

脳内微量出血模倣モデルにおける認知症関連蛋白発現機序の解明と制御 (Project/Area Number: 22K16662 )
Anti-tumor effects and Regulation of Wnt signaling pathway of adenovirus-mediated DKK3 in glioblastoma (Project/Area Number: 25462264 )
Search by Researcher Number (60710340)